Woodline Partners LP Jounce Therapeutics, Inc. Transaction History

Woodline Partners LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$6.01 - $8.54 $8.17 Million - $11.6 Million	-1,359,528 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$7.11 - $9.64 $9.67 Million - $13.1 Million	1,359,528 New	1,359,528 $11.4 Million
Q1 2021 May 17, 2021	SELL	$6.73 - $13.87 $6.33 Million - $13.1 Million	-940,902 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$6.37 - $10.33 $71,668 - $116,222	11,251 Added 1.21%	940,902 $6.59 Million
Q3 2020 Nov 16, 2020	BUY	$4.58 - $10.95 $4.26 Million - $10.2 Million	929,651 New	929,651 $7.59 Million

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

Stay updated on Woodline Partners LP with notifications on news.